The company achieved a significant milestone with acceptance of Phase 2a pancreatic cancer study data at a prestigious international oncology conference (ESMO). The study demonstrated encouraging survival outcomes and durable disease stabilization in a difficult-to-treat patient population, supporting continued development and advancement to Phase 2b combination therapy trials.
The company successfully met its primary safety endpoint in the Phase IIa pancreatic cancer study with a favorable safety profile and no new safety signals. The positive safety data supports continued clinical evaluation and strengthens the drug candidate's development prospects. Additionally, the company is advancing multiple pipeline candidates across cancer and inflammatory disease indications.
Articles that tag CANF but are mainly about other companies.
Initiated pivotal Phase III psoriasis study of Piclidenoson with FDA and EMA approval in March 2025, representing significant progress toward regulatory submission and commercialization.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
